NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW) Short Interest Update

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPWGet Free Report) was the recipient of a large drop in short interest in February. As of February 15th, there was short interest totalling 1,200 shares, a drop of 89.1% from the January 31st total of 11,000 shares. Based on an average daily trading volume, of 23,700 shares, the days-to-cover ratio is presently 0.1 days.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ:NRXPW traded up $0.00 during trading on Thursday, reaching $0.10. The stock had a trading volume of 2,924 shares, compared to its average volume of 35,647. The business has a fifty day moving average price of $0.19 and a 200-day moving average price of $0.11. NRx Pharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.50.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

Further Reading

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.